Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pneucolin
- Development stage
- Phase 4
- Lead developer
- WANTAI BioPharm
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Pneucolin is an intranasal COVID-19 vaccine that utilizes a live-attenuated influenza virus (LAIV) vector to deliver the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Developed through a collaboration between Xiamen University, the University of Hong Kong, and Beijing Wantai Biological Pharmacy Enterprise, the vaccine is designed to elicit mucosal immunity in the respiratory tract, alongside systemic humoral and cellular immune responses. The vector is a delNS1 (NS1-deleted) influenza virus, which is replication-deficient in normal cells but capable of expressing the recombinant SARS-CoV-2 RBD gene. Pneucolin has received Emergency Use Authorization in China for use as a booster, particularly in adults with hybrid immunity, and is administered via a nasal spray to mimic the natural route of infection.
- Brand names
- Pneucolin
- Other names
- Influenza Virus Vector COVID-19 Vaccine for Intranasal SprayIntranasal SARS-CoV-2 vaccineDelNS1-nCoV-RBDDelNS-1-nCoV-RBDDelNS 1-nCoV-RBD
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Pneucolin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pneucolin.